Prospect News: News for Valeant Pharmaceuticals International

E-mail us: service@prospectnews.com Or call: 212 374 2800

Bank Loans - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products

Add to balance / Manage account

Not logged in

Prospect News home > Main news index > All issuers starting with V > Issuers starting with V, CV only > All stories on Valeant Pharmaceuticals International > Stories on Valeant Pharmaceuticals International, CV only

Search again

Enter part or all of the issuer name:

Market:

All markets No structured products Bank loans Canadian bonds CLOs Convertibles Distressed debt Emerging markets High yield Investment grade Liability management Municipals PIPEs Preferreds Private placements All leveraged markets Structured products

Market: BK = Bank loans, CV = Convertibles, DD = Distressed Debt, EM = Emerging Markets, HY = High Yield, IG = Investment Grade, LM = Liability Management, MU = Municipals, PP = PIPEs, PF = Preferreds, PV = Private Placements, SP = Structured Products
Recent items, highlighted in orange, are $4.00 each. All others are $1.00 each. Headlines in gray are not currently covered by your subscription.

Valeant Pharmaceuticals International

5/8/2018	BKCVDDEMIGPV	Market Commentary: Primary quiet; Gaming & Leisure active; Dish volatile; Sanchez Energy drops, Valeant gains
9/21/2012	BKCVHY	Moody's: Valeant unaffected
5/3/2011	BKCACVHY	Moody's confirms Valeant
3/9/2011	BKCACVHY	S&P rates Valeant notes BB-
3/2/2011	BKCACVHY	Moody's cuts Valeant to stable, rates notes Ba3
3/2/2011	BKCACVHY	S&P rates Valeant notes BB-
3/1/2011	CVLM	Valeant Pharmaceuticals plans to redeem 4% convertibles due 2013
2/7/2011	BKCACVHY	S&P assigns Valeant loan BB+, notes BB-
2/3/2011	BKCACVHY	Moody's rates Valeant notes B1
2/3/2011	BKCACVHY	S&P rates Valeant notes BB-
11/18/2010	CV	Moody's rates Valeant notes B1
9/22/2010	BKCVHY	S&P revises Valeant notes to BB-
9/9/2010	CVHY	S&P rates Valeant loan BB+
9/8/2010	CV	Moody's rates Valeant Ba3
6/22/2010	CV	Market Commentary: Teva series Ds active in trade; Transocean ends lower; Biovail, Lincare better; PPL adds
6/21/2010	CV	Market Commentary: Biovail gains on merger with Valeant; Amgen up on competitor's drug safety; PPL on tap
6/21/2010	CVHY	Moody's: Valeant unchanged
5/26/2010	CV	UAL convertibles, other in-the-money paper could see premium expansion in down market: Epstein
4/6/2010	CVHY	S&P lifts Valeant, rates notes BB-
4/6/2010	CVHY	Moody's assigns Valeant notes Ba3
3/30/2010	CVHY	Valeant may buy back up to $500 million more notes, convertible debt
1/8/2010	BWCVHY	Valeant CEO says recent acquisitions position company for growth
9/23/2009	BWCVHYSS	Valeant Pharmaceuticals narrows focus, looks for double-digit growth
8/24/2009	CV	Market Commentary: AMD finds buyers, gains on Citi upgrade; SanDisk adds; Valeant holds in after failed trial
8/14/2009	CV	Valeant Pharmaceuticals to pay cash, issue warrants in exchange for $55.93 million 3% convertibles
5/29/2009	CVHY	Moody's rates Valeant B1, notes Ba3
5/28/2009	CV	Valeant ups repurchase program for convertibles, stock to $500 million
5/28/2009	CVHY	S&P: Valeant view positive
5/18/2009	CV	Market Commentary: Convertibles secondary market mostly quiet as equities surge; Covanta, AngloGold to price
12/10/2008	CVHY	Valeant redeems $33 million of convertibles in November
7/31/2008	CVHY	S&P ups Valeant
6/11/2007	CVHY	S&P: Valeant unaffected
2/1/2007	CVHY	S&P affirms Valeant
1/24/2007	CVHY	Moody's confirms Valeant
12/18/2006	CVHY	Moody's drops Valeant
12/14/2006	CVDD	Valeant Pharmaceuticals receives default notice on 3% convertible notes due 2010
11/16/2006	BTCVHY	S&P drops Valeant Pharmaceuticals
10/24/2006	BTCVHY	Moody's may downgrade Valeant
10/24/2006	BTCVHY	S&P puts Valeant on watch
10/23/2006	BTCVDDHY	Valeant Pharmaceuticals 10-Q filing delay could prompt high-yield, convertible notes defaults
9/21/2006	BKBTCVHY	Moody's revises ratings for nine U.S. pharma companies
3/23/2006	BTCVHY	Moody's affirms Valeant Pharmaceuticals
11/29/2005	BTCVHY	S&P: Valeant unaffected
9/29/2005	BTCVHY	S&P lifts Valeant view to stable
2/2/2005	CVHY	S&P affirms Valeant Pharmaceuticals
10/19/2004	CV	Merrill Lynch recommends Valeant 4% convertible on attractive price, positive view on stock
6/21/2004	CV	Valeant calls $236.6 million 61/2% convertibles
2/13/2004	CVHY	S&P: Valeant unaffected
12/4/2003	CVHY	Moody's rates Valeant senior notes B1
11/25/2003	CVHY	S&P rates new Valeant notes BB-
11/19/2003	CV	Valeant greenshoe exercised, raising convertibles to $480 million
11/14/2003	CV	New Issue: Valeant sells $400 million convertibles; Tranche A at 3%, up 40%; Tranche B at 4%, up 40%
11/14/2003	CV	Market Commentary: Valeant 3s end at 103.75 bid, 4s end at 104.75 bid; Amgen converts resist slide with stock
11/13/2003	CV	Valeant launches $400 million convertibles in 6.75-year, 10-year tranches
11/13/2003	CV	Market Commentary: Both Valeant tranches bid up 2 points in gray, Radisys up 2.5; Casual Male adds 2.5
11/13/2003	CVHY	S&P rates Valeant convertibles B

©2025 Prospect News. This page is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies, faxing, photocopying or any other form of reproduction.